Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Cancer Discov. 2021 May 3;11(10):2474–2487. doi: 10.1158/2159-8290.CD-20-1557

Figure 2. Pathological response according to HER2 heterogeneity and hormone receptor status.

Figure 2.

The mean and 95% confidence interval of the mean is shown in each graph. A, pCR by HER2 heterogeneity. B, Pathological response defined as RCB 0 or I by HER2 heterogeneity. C, pCR by hormone receptor (HR) status for the overall study population. A-C, P-values are from a χ2 test.